Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott J. Rodig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Scott Rodig and Mohamed Sayegh.
Connection Strength

0.307
  1. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 01; 187(3):1113-9.
    View in: PubMed
    Score: 0.122
  2. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24.
    View in: PubMed
    Score: 0.100
  3. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol. 2011 Jan 01; 186(1):121-31.
    View in: PubMed
    Score: 0.029
  4. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010 Sep; 59(9):2253-64.
    View in: PubMed
    Score: 0.029
  5. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009 Jul 15; 183(2):993-1004.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.